Sign in
4

Changes in Ownership

Vaxcyte, Inc. Filed Acc 0001649094-25-000012

SVP, GEN COUNSEL & CORP SEC sold 5,000 shares at an average $90.07 ($450,369)

  • SVP, GEN COUNSEL & CORP SEC acquired 5,000 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC 2025-02-05 Option exercise 10b5-1 +5,000 $21.41 $107,050 33,222 D: show line 1 in the form
Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC 2025-02-05 Sale 10b5-1 −571 $87.77 $50,115 32,651 D: show line 2 in the form
Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC 2025-02-05 Sale 10b5-1 −635 $89.09 $56,571 32,016 D: show line 3 in the form
Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC 2025-02-05 Sale 10b5-1 −1,755 $89.95 $157,860 30,261 D: show line 4 in the form
Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC 2025-02-05 Sale 10b5-1 −1,784 $91.05 $162,437 28,477 D: show line 5 in the form
Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC 2025-02-05 Sale 10b5-1 −255 $91.71 $23,386 28,222 D: show line 6 in the form
Open-market sales · 5,000 sh · avg $90.07 · $450,369

Table II: Derivative

Insider Date Transaction Shares Price Value Exercise Expires Underlying Owned after D/I
Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC 2025-02-05 Option exercise · Stock Option (right to buy) 10b5-1 −5,000 149,497 D: show line 7 in the form
Loading xslF345X05/wk-form4_1738962245.xml…